LBA 45 Lapauw, B
Naming each disease causing lung failure inflates the word count but adds no clinical nuance
Xtandi (enzalutamide) Disease area(s): Oncology Manufacturer(s): Astellas/Pfizer 2024 Sales (USD): $7.94 billion Why it sold so well: In 2024, Astellas Pharmas Xtandi, co-marketed with Pfizer, posted strong sales growth, with revenues reaching 703.1 billion ($4.64 billion) for the first nine months (April 1, 2024 to December 31, 2024), marking a 25.6% increase compared to the same period in the previous year
Methylene blue and COVID-19 Due to its antiviral activity, methylene blue has been explored as a potential treatment for COVID-19
Every filler, biostimulator, and tightening treatment is planned around proportion, structure, and natural-looking harmony